{"id":623,"date":"2026-02-28T13:43:00","date_gmt":"2026-02-28T13:43:00","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/cha2ds2-vasc-score-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T13:43:00","modified_gmt":"2026-02-28T13:43:00","slug":"cha2ds2-vasc-score-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/cha2ds2-vasc-score-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"CHA2DS2 VASc Score: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">CHA2DS2 VASc Score Introduction (What it is)<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score is a clinical risk score used to estimate stroke and systemic embolism risk.<br\/>\nIt belongs to the category of <strong>risk stratification scores<\/strong> used in cardiovascular medicine.<br\/>\nIt is most commonly encountered when caring for patients with <strong>atrial fibrillation<\/strong> (AF) or <strong>atrial flutter<\/strong>.<br\/>\nClinicians use it to support shared decision-making about preventive strategies, often including anticoagulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why CHA2DS2 VASc Score matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Atrial fibrillation is a common arrhythmia in which the atria activate rapidly and irregularly, leading to ineffective atrial contraction and variable ventricular response. One of the major clinical concerns in AF is <strong>thromboembolism<\/strong>, particularly <strong>ischemic stroke<\/strong>, which can occur when a thrombus forms in the left atrium (often the left atrial appendage) and embolizes to the cerebral circulation.<\/p>\n\n\n\n<p>The CHA2DS2 VASc Score matters because it provides a structured way to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Estimate baseline thromboembolic risk<\/strong> in people with AF or atrial flutter.<\/li>\n<li><strong>Standardize communication<\/strong> among clinicians and learners (e.g., documenting risk factors clearly).<\/li>\n<li><strong>Support treatment planning<\/strong> by identifying patients more likely to benefit from stroke prevention strategies.<\/li>\n<li><strong>Frame discussions about risk vs benefit<\/strong>, since therapies that reduce stroke risk (notably anticoagulants) can increase bleeding risk.<\/li>\n<\/ul>\n\n\n\n<p>From an education standpoint, the score is also a practical tool for learning how common cardiovascular comorbidities cluster together. Each component represents a clinical condition that contributes to vascular risk through mechanisms such as endothelial dysfunction, inflammation, hypercoagulability, and structural heart disease. In real-world care, how the score is used can vary by guideline, clinician judgment, and patient-specific factors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score itself is a single scoring system rather than a disease with stages or subtypes. The closest relevant \u201cclassification\u201d is how it relates to other stroke-risk tools and AF categories:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Related scoring systems<\/strong><\/li>\n<li><strong>CHADS2<\/strong>: an older, simpler score that preceded CHA2DS2 VASc Score.<\/li>\n<li>\n<p><strong>Bleeding risk scores (e.g., HAS-BLED)<\/strong>: commonly considered alongside stroke-risk scores to contextualize anticoagulation decisions. These measure different outcomes and are not direct substitutes for each other.<\/p>\n<\/li>\n<li>\n<p><strong>AF context in which the score is applied<\/strong><\/p>\n<\/li>\n<li><strong>Paroxysmal, persistent, and permanent AF<\/strong>: AF pattern affects rhythm-control decisions, but thromboembolic risk assessment is generally based on patient risk factors rather than AF \u201ctype\u201d alone.<\/li>\n<li><strong>\u201cValvular\u201d vs \u201cnon-valvular\u201d AF (clinical shorthand)<\/strong>: Many teaching resources use this distinction to highlight that some conditions (notably mechanical heart valves and moderate-to-severe rheumatic mitral stenosis) follow different anticoagulation frameworks, and CHA2DS2 VASc Score may be less applicable or not the primary determinant in those settings.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Understanding why CHA2DS2 VASc Score exists is easier when you connect AF-related clot risk to basic cardiovascular anatomy and flow.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atria and ventricles<\/strong><\/li>\n<li>The <strong>left atrium<\/strong> receives oxygenated blood from the pulmonary veins and delivers it across the <strong>mitral valve<\/strong> into the left ventricle.<\/li>\n<li>\n<p>In normal sinus rhythm, atrial contraction contributes to ventricular filling (\u201catrial kick\u201d), especially important when ventricular relaxation is impaired.<\/p>\n<\/li>\n<li>\n<p><strong>Left atrial appendage (LAA)<\/strong><\/p>\n<\/li>\n<li>The LAA is a small outpouching of the left atrium with complex internal anatomy.<\/li>\n<li>\n<p>In AF, reduced coordinated atrial contraction can promote <strong>blood stasis<\/strong>, particularly in the LAA, creating conditions favorable for thrombus formation.<\/p>\n<\/li>\n<li>\n<p><strong>Cerebral and systemic circulation<\/strong><\/p>\n<\/li>\n<li>Emboli arising from the left heart can travel through the <strong>aorta<\/strong> to the <strong>carotid<\/strong> or <strong>vertebrobasilar<\/strong> circulation, causing ischemic stroke.<\/li>\n<li>\n<p>Emboli can also lodge in other arterial beds (systemic embolism), depending on size and vascular anatomy.<\/p>\n<\/li>\n<li>\n<p><strong>Vascular endothelium and hemostasis<\/strong><\/p>\n<\/li>\n<li>The coagulation system balances prothrombotic and antithrombotic forces.<\/li>\n<li>Conditions included in CHA2DS2 VASc Score (e.g., hypertension, diabetes, vascular disease, older age, prior stroke) are associated with changes in vascular biology that can increase thrombotic propensity.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score does not measure a lab value or imaging parameter; it estimates risk based on clinical variables that correlate with thromboembolism in AF. The \u201cmechanism\u201d is therefore a combination of AF-related flow abnormalities plus patient-level vascular risk.<\/p>\n\n\n\n<p>A useful framework is <strong>Virchow\u2019s triad<\/strong>, which describes contributors to thrombosis:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stasis of blood flow<\/strong><\/li>\n<li>AF causes disorganized atrial electrical activity and ineffective mechanical contraction.<\/li>\n<li>\n<p>Reduced atrial emptying promotes stasis, especially in the LAA.<\/p>\n<\/li>\n<li>\n<p><strong>Endothelial injury or dysfunction<\/strong><\/p>\n<\/li>\n<li>Chronic hypertension and vascular disease contribute to endothelial dysfunction and arterial remodeling.<\/li>\n<li>\n<p>Diabetes is associated with microvascular and macrovascular injury, inflammation, and altered platelet function.<\/p>\n<\/li>\n<li>\n<p><strong>Hypercoagulability<\/strong><\/p>\n<\/li>\n<li>Older age and systemic inflammatory states can shift hemostatic balance.<\/li>\n<li>Prior thromboembolism suggests an individual has already demonstrated susceptibility to clot-related events.<\/li>\n<\/ul>\n\n\n\n<p>Each CHA2DS2 VASc Score component reflects a clinical marker that, alone or in combination, increases the probability of thrombus formation and\/or embolic complications in the setting of AF. Importantly, risk is not uniform; it varies across patients and can change over time as comorbidities develop.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score is typically used in these scenarios:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A patient is diagnosed with <strong>atrial fibrillation<\/strong> on electrocardiogram (ECG) in clinic, the emergency department, or during hospitalization.<\/li>\n<li>A patient has <strong>atrial flutter<\/strong>, and the team is considering a similar thromboembolic risk framework.<\/li>\n<li>AF is discovered incidentally (e.g., on telemetry, wearable device tracing reviewed clinically, or preoperative ECG), and stroke prevention is being discussed.<\/li>\n<li>A patient with known AF is being reevaluated because new comorbidities have developed (e.g., new heart failure diagnosis or aging into an older risk category).<\/li>\n<li>A clinician is documenting risk to guide conversations about <strong>anticoagulation<\/strong> and to coordinate care across settings (primary care, cardiology, neurology).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">How the score is determined (components)<\/h3>\n\n\n\n<p>CHA2DS2 VASc Score is calculated from routinely available clinical history. The acronym expands to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C<\/strong>: Congestive heart failure (or clinical heart failure\/left ventricular dysfunction)<\/li>\n<li><strong>H<\/strong>: Hypertension<\/li>\n<li><strong>A2<\/strong>: Age in the older age band (counts more heavily than younger age)<\/li>\n<li><strong>D<\/strong>: Diabetes mellitus<\/li>\n<li><strong>S2<\/strong>: Prior stroke, transient ischemic attack (TIA), or systemic thromboembolism (counts more heavily)<\/li>\n<li><strong>V<\/strong>: Vascular disease (commonly includes prior myocardial infarction, peripheral arterial disease, or aortic plaque, depending on definitions used)<\/li>\n<li><strong>A<\/strong>: Age in an intermediate older age band<\/li>\n<li><strong>Sc<\/strong>: Sex category (female sex as a risk modifier in many references)<\/li>\n<\/ul>\n\n\n\n<p>Some elements contribute more points than others (notably prior stroke\/TIA\/systemic embolism and the oldest age category), reflecting their stronger association with thromboembolic risk in studied populations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Clinical information needed<\/h3>\n\n\n\n<p>Clinicians typically gather:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>History<\/strong><\/li>\n<li>Prior stroke\/TIA or systemic embolism history<\/li>\n<li>Hypertension history (including treatment)<\/li>\n<li>Diabetes diagnosis<\/li>\n<li>Symptoms or diagnosis of heart failure<\/li>\n<li>Known vascular disease (coronary, peripheral, aortic)<\/li>\n<li>\n<p>Age and sex<\/p>\n<\/li>\n<li>\n<p><strong>Supporting data (as needed)<\/strong><\/p>\n<\/li>\n<li>Echocardiography findings for ventricular function when heart failure status is unclear<\/li>\n<li>Prior cardiology records for vascular history<\/li>\n<li>Problem lists and medication review to confirm diagnoses<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">How clinicians interpret it conceptually<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The score is used to <strong>stratify thromboembolic risk<\/strong>: generally, more risk factors correspond to higher estimated risk.<\/li>\n<li>It helps structure discussions about <strong>stroke prevention<\/strong> strategies, most commonly whether to use anticoagulation and how urgently to address risk.<\/li>\n<li>Interpretation is <strong>not purely automatic<\/strong>. Clinical context matters, such as:<\/li>\n<li>Whether AF is present and confirmed<\/li>\n<li>Whether AF is related to reversible triggers (risk assessment may still be considered, but management plans can differ)<\/li>\n<li>Whether the patient has conditions where CHA2DS2 VASc Score is not the main framework (e.g., certain valvular conditions)<\/li>\n<\/ul>\n\n\n\n<p>Because clinical guidelines differ in how they apply specific thresholds and because patient preferences and bleeding risks vary, exact decision pathways can be \u201cVaries by clinician and case.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score is not a treatment; it is a tool that fits into a broader AF care pathway. Management typically has parallel goals:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\n<p><strong>Confirm and characterize the rhythm problem (AF or flutter)<\/strong>\n   &#8211; ECG documentation and clinical assessment\n   &#8211; Evaluation for triggers and comorbidities (thyroid disease, sleep apnea risk, structural heart disease)<\/p>\n<\/li>\n<li>\n<p><strong>Assess stroke and bleeding risk<\/strong>\n   &#8211; Stroke risk estimation using CHA2DS2 VASc Score\n   &#8211; Bleeding risk assessment using clinical history and, in some cases, a bleeding risk score\n   &#8211; Review of medication interactions and fall\/trauma risk factors as appropriate<\/p>\n<\/li>\n<li>\n<p><strong>Stroke prevention strategy (general categories)<\/strong>\n   &#8211; <strong>No anticoagulation<\/strong> may be reasonable in some low-risk situations, depending on guideline framework and patient factors.\n   &#8211; <strong>Oral anticoagulation<\/strong> is commonly considered when stroke risk is judged to outweigh bleeding risk.<\/p>\n<ul>\n<li>Options often include <strong>direct oral anticoagulants (DOACs)<\/strong> and <strong>vitamin K antagonists<\/strong> (e.g., warfarin). Choice can depend on comorbidities, kidney function, drug interactions, cost, adherence considerations, and specific clinical conditions.<\/li>\n<li><strong>Left atrial appendage occlusion<\/strong> (device-based approaches) may be considered in selected patients who have AF with elevated stroke risk and challenges with long-term anticoagulation, depending on patient factors and institutional practice.<\/li>\n<\/ul>\n<\/li>\n<li>\n<p><strong>Rhythm and rate management (related but distinct)<\/strong>\n   &#8211; <strong>Rate control<\/strong> medications aim to control ventricular rate.\n   &#8211; <strong>Rhythm control<\/strong> strategies (antiarrhythmic drugs, cardioversion, catheter ablation) aim to reduce AF burden or restore sinus rhythm.\n   &#8211; A key teaching point: successful rhythm control does not automatically eliminate thromboembolic risk for every patient; anticoagulation decisions are typically based on overall risk profile and clinical context.<\/p>\n<\/li>\n<li>\n<p><strong>Risk factor modification and longitudinal care<\/strong>\n   &#8211; Management of hypertension, diabetes, heart failure, and vascular disease\n   &#8211; Lifestyle and preventive cardiology measures as appropriate (general education; specific plans vary)<\/p>\n<\/li>\n<\/ol>\n\n\n\n<p>This is an educational overview only; specific decisions and timing vary by protocol and patient factors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>CHA2DS2 VASc Score is widely used, but it has limitations and must be applied thoughtfully.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Not a direct measurement<\/strong><\/li>\n<li>\n<p>It estimates risk based on population-level associations and does not directly measure clot burden, atrial appendage flow, or hypercoagulability.<\/p>\n<\/li>\n<li>\n<p><strong>Potential for misclassification<\/strong><\/p>\n<\/li>\n<li>Incomplete medical history (e.g., undocumented prior TIA) can underestimate risk.<\/li>\n<li>\n<p>Differences in how \u201cvascular disease\u201d or \u201cheart failure\u201d are defined can change scoring.<\/p>\n<\/li>\n<li>\n<p><strong>Sex category nuance<\/strong><\/p>\n<\/li>\n<li>\n<p>Female sex is often treated as a risk modifier rather than a stand-alone driver of anticoagulation decisions; how this is applied can vary by guideline and clinician judgment.<\/p>\n<\/li>\n<li>\n<p><strong>May be less applicable in certain conditions<\/strong><\/p>\n<\/li>\n<li>\n<p>In some patients with mechanical valves or significant rheumatic mitral stenosis, anticoagulation decisions may follow different evidence bases, and CHA2DS2 VASc Score may not be the primary tool.<\/p>\n<\/li>\n<li>\n<p><strong>Does not replace bleeding risk assessment<\/strong><\/p>\n<\/li>\n<li>\n<p>Stroke risk and bleeding risk are different domains; anticoagulation decisions often require balancing both, plus patient values and practical considerations.<\/p>\n<\/li>\n<li>\n<p><strong>Risk changes over time<\/strong><\/p>\n<\/li>\n<li>Aging and new diagnoses (hypertension, diabetes, heart failure) can increase risk, so a \u201cone-time\u201d score may become outdated.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>In AF, prognosis depends on multiple overlapping issues: arrhythmia burden, symptom control, ventricular function, comorbidities, and thromboembolic risk.<\/p>\n\n\n\n<p>Follow-up considerations related to CHA2DS2 VASc Score commonly include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Periodic reassessment<\/strong><\/li>\n<li>\n<p>Stroke risk can increase as patients age or develop new comorbidities. Recalculation at intervals is common in longitudinal care.<\/p>\n<\/li>\n<li>\n<p><strong>Monitoring for therapy effects and safety<\/strong><\/p>\n<\/li>\n<li>If anticoagulation is used, follow-up often focuses on bleeding symptoms, drug interactions, kidney\/liver function considerations (depending on agent), and adherence challenges.<\/li>\n<li>\n<p>If warfarin is used, monitoring intensity differs from DOACs due to INR-based management.<\/p>\n<\/li>\n<li>\n<p><strong>Ongoing AF management<\/strong><\/p>\n<\/li>\n<li>Rate\/rhythm strategies can evolve over time.<\/li>\n<li>\n<p>Management of contributing conditions (hypertension, heart failure, diabetes, vascular disease) can influence overall cardiovascular outcomes.<\/p>\n<\/li>\n<li>\n<p><strong>Outcome expectations<\/strong><\/p>\n<\/li>\n<li>The score helps frame risk but does not guarantee an outcome for any one person. Actual prognosis varies by underlying etiology, access to care, comorbidity severity, and individualized treatment decisions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">CHA2DS2 VASc Score Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does CHA2DS2 VASc Score stand for?<\/strong><br\/>\nIt is an acronym for common stroke risk factors in atrial fibrillation: congestive heart failure, hypertension, age (with older age weighted more), diabetes, prior stroke\/TIA\/systemic embolism (weighted more), vascular disease, age (intermediate band), and sex category. The letters correspond to clinical conditions, not lab tests. The purpose is to summarize risk factors in a consistent way.<\/p>\n\n\n\n<p><strong>Q: Is CHA2DS2 VASc Score used only for atrial fibrillation?<\/strong><br\/>\nIt is primarily used for atrial fibrillation and often atrial flutter because the major concern is embolic stroke from left-sided cardiac thrombus. It is not designed as a general \u201cstroke predictor\u201d for people without AF. In other rhythm conditions, different clinical reasoning and tools may be more appropriate.<\/p>\n\n\n\n<p><strong>Q: Does paroxysmal (intermittent) AF count the same as persistent AF for this score?<\/strong><br\/>\nThe score is based on patient risk factors rather than how often AF occurs. Many clinical approaches treat thromboembolic risk as related more to underlying comorbidities than AF pattern alone. Individual management decisions can still vary by clinician and case.<\/p>\n\n\n\n<p><strong>Q: If someone\u2019s CHA2DS2 VASc Score is higher, what does that mean?<\/strong><br\/>\nA higher score generally indicates more clinical factors associated with thromboembolic risk in AF. It suggests a greater baseline probability of stroke\/systemic embolism compared with someone with fewer risk factors. The score is used to support discussions about preventive strategies, not to predict a specific individual outcome.<\/p>\n\n\n\n<p><strong>Q: What counts as \u201cvascular disease\u201d in the score?<\/strong><br\/>\nDefinitions vary slightly across references and protocols. Common inclusions are prior myocardial infarction, peripheral arterial disease, and sometimes aortic plaque. When documentation is unclear, clinicians may verify past records or imaging summaries.<\/p>\n\n\n\n<p><strong>Q: Why are age and prior stroke weighted more heavily?<\/strong><br\/>\nOlder age and a history of stroke\/TIA\/systemic embolism are strongly associated with future thromboembolic events in AF populations studied. Weighting reflects the fact that these factors tend to carry more prognostic information than some other single comorbidities. Exact weighting is part of the score\u2019s validated structure.<\/p>\n\n\n\n<p><strong>Q: Does restoring normal rhythm remove the need to think about CHA2DS2 VASc Score?<\/strong><br\/>\nNot necessarily. Even if sinus rhythm is restored, many care pathways base stroke prevention decisions on underlying risk factors rather than rhythm status at a single moment. AF can recur silently, and thromboembolic risk may persist due to atrial cardiomyopathy and comorbidities. Decisions vary by protocol and patient factors.<\/p>\n\n\n\n<p><strong>Q: Is CHA2DS2 VASc Score the same as a bleeding risk score?<\/strong><br\/>\nNo. CHA2DS2 VASc Score estimates thromboembolic risk, while bleeding risk scores estimate the likelihood of bleeding complications, particularly when anticoagulants are used. Clinicians often consider both domains to contextualize risks and benefits. They answer different questions and should not be used interchangeably.<\/p>\n\n\n\n<p><strong>Q: What are typical next steps after calculating the score?<\/strong><br\/>\nCommon next steps include confirming the AF diagnosis, documenting the individual risk factors clearly, and discussing stroke prevention options in the context of bleeding risk and patient preferences. Clinicians may also address modifiable contributors like blood pressure control and diabetes management as part of overall cardiovascular risk reduction. Specific actions vary by clinician and case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHA2DS2 VASc Score is a clinical risk score used to estimate stroke and systemic embolism risk. It belongs to the category of **risk stratification scores** used in cardiovascular medicine. It is most commonly encountered when caring for patients with **atrial fibrillation** (AF) or **atrial flutter**. Clinicians use it to support shared decision-making about preventive strategies, often including anticoagulation.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-623","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=623"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/623\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}